Drugs / Pelcitoclax
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07428486 | Apr 2026 | T lymphoblastic leukemia/lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT05691504 | Sep 2023 → Feb 2027 expected | endometrial carcinoma, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma +1 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04893759 | Jan → Sep 2022 | neuroendocrine neoplasm | Ascentage Pharma Group Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04001777 | Jul 2019 → Dec 2025 overdue | non-small cell lung carcinoma | Ascentage Pharma Group Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03387332 | Dec 2017 → Nov 2020 | small cell lung carcinoma | Ascentage Pharma Group Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03080311 | Feb 2017 → Jun 2020 | small cell lung carcinoma | Ascentage Pharma Group Inc. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07508982 | May 2026 → Dec 2029 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05186012 | Jun 2022 → Sep 2025 | non-Hodgkin lymphoma | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04354727 | Dec 2020 → Dec 2022 | myelofibrosis | Ascentage Pharma Group Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04210037 | Aug 2020 → Aug 2021 | small cell lung carcinoma | Ascentage Pharma Group Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pelcitoclax | “Patients received intravenous pelcitoclax (160 mg in dose-expansion and either 160 or 240 mg in dose-escalation) weekly and oral osimertinib 80 mg daily.” PMID 42442920 ↗ Jul 2026 |
| Known as | APG-1252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04210037 ↗ |
| Action | Inhibit | “Bcl-2 family protein inhibitor” NCT03080311 ↗ |
| Modality | Small molecule | — CHEMBL4802151 ↗ |
| Route | Intravenous | “APG-1252 intravenous administration on Days 1, 4, 8, 11, 15, 18 and 22” NCT03080311 ↗ |